Natera IPO

7/2/2015

IPO

$180,000,000

The principal purposes of this offering are to increase our financial flexibility, increase our visibility in the marketplace, create a public market for our common stock, obtain additional working capital and facilitate our future access to the public equity markets. We currently intend to use approximately $59.1 million of the net proceeds received by us from this offering for working capital and general corporate purposes and approximately $100.0 million for continued investments in research and development for our core technology and development of our product offerings. In addition, we may use a portion of the net proceeds received by us from this offering for acquisitions of complementary businesses, technologies or other assets. However, we have no current understandings, agreements or commitments for any material acquisitions at this time, and we have not allocated specific amounts of the net proceeds received by us from this offering for any of these purposes. We have not yet

Publicly-held

Biopharmaceutical

201 Industrial Rd. 410
San Carlos, CA 94070
USA

Natera (NASDAQ: NTRA) is a genetic testing company that has developed a proprietary bioinformatics technology to deliver accurate and comprehensive high throughput testing for reproductive indications from tiny quantities of DNA -- as small as that from a single cell.